Carnegie Lake Advisors LLC Acquires 16,400 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Carnegie Lake Advisors LLC lifted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 23.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 85,350 shares of the company’s stock after purchasing an additional 16,400 shares during the period. Carnegie Lake Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $1,312,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Oarsman Capital Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $29,000. Golden State Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $44,000. Compagnie Lombard Odier SCmA purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter worth about $54,000. Finally, Versant Capital Management Inc boosted its stake in shares of Teva Pharmaceutical Industries by 437.8% during the 1st quarter. Versant Capital Management Inc now owns 5,297 shares of the company’s stock worth $81,000 after acquiring an additional 4,312 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Activity

In other news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares of the company’s stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.49% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Friday. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research note on Friday, June 6th. They issued a “buy” rating and a $24.00 price target on the stock. Truist Financial began coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $23.00 in a research note on Monday, May 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $24.71.

Teva Pharmaceutical Industries Stock Down 1.4%

Shares of NYSE TEVA opened at $16.08 on Friday. The company has a 50 day simple moving average of $17.01 and a 200-day simple moving average of $16.97. The company has a market capitalization of $18.44 billion, a P/E ratio of -13.98, a P/E/G ratio of 0.96 and a beta of 0.60. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. During the same quarter last year, the firm earned $0.48 EPS. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.